-
Fenofibrate, Aging, and the PPARα–YAP Axis
2026-09-10
The reference study shows that fenofibrate produces comparable liver enlargement and activates the PPARα–YAP signaling axis in adult and aging mouse models. Its findings suggest that aging does not substantially weaken fenofibrate-associated hepatocyte hypertrophy, proliferation, or downstream PPARα responses, while also highlighting important limits for translating mouse liver remodeling to human treatment.
-
EdU Imaging Kits for RCC Proliferation
2026-09-10
EdU Imaging Kits (HF488) convert S-phase DNA synthesis into a sensitive fluorescence readout for RCC drug-response studies, including syringin–sunitinib experiments. The antibody-free click-chemistry workflow supports both spatial microscopy and quantitative flow cytometry while preserving morphology and antigen-accessible epitopes.
-
Boc-D-FMK: Linking Apoptosis to Drug Metabolism
2026-09-09
Boc-D-FMK is a cell-permeable pan-caspase inhibitor for separating caspase-dependent cell death from transcriptional changes in drug metabolism. This article develops a decision framework connecting apoptosis research with the ATF5–CYP2B6 findings reported in glioblastoma cells.
-
Cinoxacin: In Vitro Activity and Resistance
2026-09-09
The 1975 study by Lumish and Norden established Cinoxacin as a synthetic quinolone antibiotic with useful in vitro activity against many aerobic gram-negative bacilli, especially Escherichia coli. Its principal contributions were a systematic MIC survey, validation of disk diffusion against agar dilution, demonstration of bactericidal activity, and an early warning that resistance could emerge during serial drug exposure.
-
Z-VEID-FMK in Host–Virus Caspase-6 Assays
2026-09-08
Z-VEID-FMK is a cell-permeable caspase-6 inhibitor for testing whether protease activity drives apoptosis or viral immune evasion. This article develops an assay strategy around PRRSV N-protein cleavage, linking catalytic inhibition to IRF3, interferon, and replication readouts.
-
Gamithromycin PK/PD in Bovine Respiratory Disease
2026-09-07
This prospective clinical study linked gamithromycin exposure in plasma and pulmonary epithelial lining fluid (PELF) with treatment outcomes in naturally occurring bovine respiratory disease. Its key contribution was an individual-level PK/PD framework showing that higher exposure relative to pathogen MIC, particularly PELF AUC0–24/MIC for Pasteurella multocida, was associated with treatment success.
-
Fumagillin Against Azumiobodo hoyamushi
2026-09-07
Park and colleagues compared 20 compounds against Azumiobodo hoyamushi, identifying fumagillin as a moderately active agent in vitro rather than a leading disinfectant candidate. The study’s main contribution was to combine a broad parasite screen with validation in experimentally infected ascidians, while showing that formalin and chlorine dioxide produced the clearest reduction in parasite burden under the tested conditions.
-
I-BET151 (GSK1210151A): Practical Lab Guide
2026-09-05
I-BET151 (GSK1210151A), SKU B1500, is a selective BET bromodomain inhibitor for controlled BRD2, BRD3, and BRD4 perturbation in preclinical cancer biology workflows. This guide covers stock preparation, assay controls, apoptosis and cell-cycle readouts, and limitations when no directly matched paper protocol is available; the compound is for research use only, not diagnostic or therapeutic use.
-
Pemetrexed: From Folate Stress to Repair Strategy
2026-09-04
Pemetrexed is more than a multi-target antifolate: it is a translational probe for connecting nucleotide stress with DNA-repair state. This article outlines how to use pemetrexed disodium in cancer chemotherapy research, with malignant mesothelioma and non-small cell lung carcinoma models as strategic test systems.
-
Isoproterenol Sulfate Dihydrate in SAN Research
2026-09-04
Isoproterenol sulfate dihydrate is a non-selective β-adrenergic agonist for controlled studies of beta-adrenergic receptor signaling, cAMP/PKA pathway responses, and cardiovascular research. In human SAN-plexus assembloids, it can serve as an acute functional challenge, but agonist responsiveness alone does not establish pacemaker maturation or neuron-to-pacemaker mechanism.
-
SB743921: KSP Inhibitor Workflow for Cancer Research
2026-09-04
SB743921 enables selective KSP inhibition while helping researchers distinguish mitotic arrest from irreversible cell death. This workflow combines dose-response profiling, time-resolved viability measurements, and orthogonal apoptosis assays for more informative cancer research data.
-
Losartan: AT1 Blockade for Vascular Research
2026-09-03
Losartan is an angiotensin II receptor antagonist used to study AT1 receptor signaling, vascular tone, and hypertension research. Supplier-reported data support its use as a selective AT1 research tool, while recent evidence suggests that ARB-class signaling can also remodel collagen-rich tumor microenvironments.
-
GPX Signaling and Axonal Fusion After Nerve Injury
2026-09-02
The reference study identifies lipid peroxidation and ferroptosis signaling as dose-sensitive regulators of regenerative axonal fusion. Using genetic and pharmacological models in Caenorhabditis elegans and mice, it connects GPX inhibition to phosphatidylserine exposure, PSR-1 condensation, EFF-1-dependent fusion, and improved recovery after sciatic nerve injury.
-
Neomycin sulfate Workflows for RNA and Channel Studies
2026-09-02
Neomycin sulfate is an aminoglycoside antibiotic that functions as a mechanistic probe for structured RNA, DNA triplexes, and ryanodine receptor channels. This guide connects practical assay design with a recent allergic-rhinitis study, while clearly separating validated findings from workflow recommendations.
-
10074-G5 in the miR-196a–MYC Axis
2026-09-01
Explore how the c-Myc inhibitor 10074-G5 can interrogate the miR-196a/TERT/NFκB axis in esophageal adenocarcinoma. This mechanistic perspective connects c-Myc/Max disruption with smarter apoptosis, cell-cycle, EMT, and translational assay decisions.